Biological Coprocessors (“BCP”) is an emerging leader in commercializing unique brain signatures to objectively measure the perception of pain. The company is commercializing a non-invasive method to measure and assess an individual’s experience of pain. BCP was awarded a Small Business Innovation Research grant by the U.S. DOD to develop the technology.
Pain is a major public health problem costing by some estimates as much as $630 billion annually. Until now current pain diagnostic techniques have relied on subjective self-reporting of patients. This complicates treatment and results in a variety of other problems, including prescription drug fraud and abuse. BCP is addressing this problem by delivering a proprietary platform technology enabling a variety of product applications.